New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Imetelstat appears headed for approval after its US adcom turns into a damp squib.
The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.
Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.